Valeant Receives FDA Complete Response Letter for Vyzulta

August 11, 2017: By Jon Swedien

1 Ophthalmic NewsValeant Pharmaceuticals International has received a complete response letter (CRL) from the US FDA in response to its new drug application (NDA) for Vyzulta, the Canadian company announced Aug. 7.

Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) is a nitric oxide-donating prostaglandin analog intended to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

According to Valeant, the CRL references a current good manufacturing practice (CGMP) inspection at a Tampa, Florida, manufacturing facility belonging to its Bausch + Lomb subsidiary.

The company said the FDA did not identify any efficacy or safety concerns or request additional clinical trials for NDA approval.

Valeant said it will work closely with the agency to determine the next steps.

The US FDA had set a target action date of Aug. 24, 2017, for its decision on Vyzulta.

Bausch + Lomb and Nicox are co-developing the drug candidate. The two companies had resubmitted the NDA in early March after addressing concerns the FDA raised in a 2016 inspection of the Tampa facility.

Bausch + Lomb licensed the product candidate from Nicox in March 2010 and rebranded the drug Vyzulta in January. It was previously branded Vesneo.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

FDA Warns that Vancomycin Eye Injections May Lead to Blindness

Alcon to Launch Clareon IOL at ESCRS Meeting

Bribery Trial Testimony Focuses on Melgen’s Billing for Lucentis

VSY Biotechnology to Launch AcrivaUD Trinova Trifocal IOL at ESCRS Meeting

Valeant Launches $1 Billion Private Senior Notes Offering

STAAR Surgical Appoints Scott Barnes, MD, as New CMO

Aerie Acquires Envisia Technology for $25M to Advance Retinal Program

Carl Zeiss Meditec Announces Milestone of 1 Million SMILE Procedures

Maryland Team Wins First Phase of NEI Contest to Create Human Retina

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022